<DOC>
	<DOCNO>NCT02372227</DOCNO>
	<brief_summary>The purpose study evaluate rise dose level VS-5584 administer combination fix dose VS-6063 subject relapse malignant mesothelioma determine recommend Phase 2 dose ( RP2D ) development combination indication .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study VS-5584 Administered Combination With VS-6063 , Subjects With Relapsed Malignant Mesothelioma</brief_title>
	<detailed_description>This study comprise 2 sequential part : Part 1 ( Dose Escalation VS-5584 ) Part 2 ( Expansion ) . Up 56 evaluable subject ( i.e. , subject complete least 1 cycle [ 21 day ] therapy ) enrol , assume : - Up 6 dose level VS-5584 study Part 1 ( Dose Escalation VS-5584 ) combination fix dose VS-6063 400 mg twice daily ( BID ) maximum 6 subject enrol per VS-5584 dose level , total 36 subject ( exclusive replacement subject ) . - Up additional 20 evaluable subject may enrol Part 2 , expansion portion study . Subjects treat VS-5584 RP2D schedule determine dose escalation portion study combination fix dose VS-6063 .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Histopathologicallyconfirmed diagnosis malignant mesothelioma ( pleural peritoneal ) . Must disease relapse follow least one prior line chemotherapy . 2 . Must receive least 3 cycle firstline chemotherapy . 3 . Evaluable measurable disease assess Response Evaluation Criteria Solid Tumors ( RECIST ) . 4 . Must archival tumor tissue available biomarker analysis . A studyspecific tumor core biopsy , pleural effusion ascites sample must obtain prior treatment archival tissue available . 5 . Performance status accord Karnofsky Performance Scale ≥70 % . 6 . Fasting blood glucose ≤ 140 mg/dL ( 7.8 mmol/L ) . 7 . Adequate renal function ( creatinine ≤ 1.5x upper limit normal [ ULN ] ) and/or glomerular filtration rate ( GFR ) ≥50 mL/min . 8 . Adequate hepatic function ( total bilirubin ≤ 1.5x ULN ; AST ALT ≤ 3x ULN ) . 9 . Adequate bone marrow function ( hemoglobin ≥9.0 g/dL ; platelet ≥100 x10^9 cells/L ; absolute neutrophil count ≥1.5x10^9 cells/L ) without use hematopoietic growth factor . 1 . Have previous extra pleural pneumonectomy ( EPP ) . 2 . Gastrointestinal condition could interfere swallow absorption study drug . 3 . Uncontrolled severe concurrent medical condition ( include uncontrolled brain metastasis ) . 4 . Known history stroke cerebrovascular accident within 6 month prior first dose study drug . 5 . Any evidence serious active infection . 6 . Undergoing active treatment secondary malignancy . 7 . Cancerdirected therapy ( chemotherapy , radiotherapy ) within 21 day first dose study drug 5 halflives , whichever short . 8 . Major surgery within 28 day prior first dose study drug . 9 . Acute chronic pancreatitis . 10 . Diabetes mellitus require insulin treatment subject hemoglobin A1C ( HbA1C ) &gt; 7 % . 11 . History evidence cardiac risk . 12 . Known history malignant hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>